IL148813A0 - Method for administering a phosphodiesterase 4 inhibitor - Google Patents

Method for administering a phosphodiesterase 4 inhibitor

Info

Publication number
IL148813A0
IL148813A0 IL14881300A IL14881300A IL148813A0 IL 148813 A0 IL148813 A0 IL 148813A0 IL 14881300 A IL14881300 A IL 14881300A IL 14881300 A IL14881300 A IL 14881300A IL 148813 A0 IL148813 A0 IL 148813A0
Authority
IL
Israel
Prior art keywords
phosphodiesterase
administering
inhibitor
Prior art date
Application number
IL14881300A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp
Publication of IL148813A0 publication Critical patent/IL148813A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
IL14881300A 1999-10-29 2000-10-26 Method for administering a phosphodiesterase 4 inhibitor IL148813A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16247799P 1999-10-29 1999-10-29
US16264199P 1999-11-01 1999-11-01
US17981700P 2000-02-02 2000-02-02
PCT/US2000/029453 WO2001032165A1 (en) 1999-10-29 2000-10-26 Method for administering a phosphodiesterase 4 inhibitor

Publications (1)

Publication Number Publication Date
IL148813A0 true IL148813A0 (en) 2002-09-12

Family

ID=27388757

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14881300A IL148813A0 (en) 1999-10-29 2000-10-26 Method for administering a phosphodiesterase 4 inhibitor

Country Status (29)

Country Link
US (1) US20030212112A1 (pt)
EP (1) EP1225884A4 (pt)
JP (1) JP2003513038A (pt)
KR (1) KR20020050249A (pt)
CN (1) CN1387433A (pt)
AP (1) AP2002002446A0 (pt)
AR (1) AR026254A1 (pt)
AU (1) AU772909B2 (pt)
BG (1) BG106623A (pt)
BR (1) BR0015039A (pt)
CA (1) CA2389293A1 (pt)
CO (1) CO5271676A1 (pt)
CZ (1) CZ20021443A3 (pt)
DZ (1) DZ3249A1 (pt)
EA (1) EA200200502A1 (pt)
HK (1) HK1049105A1 (pt)
HU (1) HUP0203682A3 (pt)
IL (1) IL148813A0 (pt)
MA (1) MA25562A1 (pt)
MX (1) MXPA02004220A (pt)
NO (1) NO20021937L (pt)
NZ (1) NZ518002A (pt)
OA (1) OA12078A (pt)
PE (1) PE20011004A1 (pt)
PL (1) PL355262A1 (pt)
SK (1) SK7292002A3 (pt)
TR (1) TR200201150T2 (pt)
UY (1) UY26422A1 (pt)
WO (1) WO2001032165A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR029984A1 (es) * 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
DE10207160A1 (de) * 2002-02-20 2003-12-18 Altana Pharma Ag Darreichungsform enthaltend PDE 4-Hemmer als Wirkstoff
AU2003232828B2 (en) * 2002-05-28 2010-06-24 Takeda Gmbh Topically applicable pharmaceutical preparation
US6822114B1 (en) 2002-10-08 2004-11-23 Albemarle Corporation Process for production of fluoroalkoxy-substituted benzamides and their intermediates
ME00524B (me) 2003-03-10 2011-10-10 Astrazeneca Ab Novi postupak za dobijanje roflumilasta
TW200420554A (en) * 2003-03-31 2004-10-16 Kyowa Hakko Kogyo Kk A intra-airway administrating preparation
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
JP5383183B2 (ja) 2005-03-16 2014-01-08 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング ロフルミラストを含有する矯味された剤形
MX2012006265A (es) * 2009-12-03 2012-07-25 Opko Health Inc Formulaciones disacaridas hipersulfatadas.
CA2861594A1 (en) * 2011-12-27 2013-07-04 Celgene Corporation Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione
CN103536582A (zh) * 2013-10-12 2014-01-29 云南龙海天然植物药业有限公司 罗氟司特干粉吸入剂
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
MY121142A (en) * 1999-02-23 2005-12-30 Smithkline Beecham Corp Controlled release formulation for treating copd
AR035987A1 (es) * 1999-03-01 2004-08-04 Smithkline Beecham Corp Uso de un compuesto inhibidor de la pde 4 para la manufactura de un medicamento y el medicamento para tratar asma inducida por ejercicio

Also Published As

Publication number Publication date
PE20011004A1 (es) 2001-09-28
NO20021937L (no) 2002-05-30
TR200201150T2 (tr) 2002-09-23
EP1225884A1 (en) 2002-07-31
OA12078A (en) 2003-05-28
AU1344501A (en) 2001-05-14
NO20021937D0 (no) 2002-04-24
EA200200502A1 (ru) 2002-10-31
AU772909B2 (en) 2004-05-13
CZ20021443A3 (cs) 2003-01-15
BR0015039A (pt) 2002-06-25
HK1049105A1 (zh) 2003-05-02
CA2389293A1 (en) 2001-05-10
UY26422A1 (es) 2001-07-31
BG106623A (bg) 2003-02-28
KR20020050249A (ko) 2002-06-26
HUP0203682A2 (hu) 2003-04-28
JP2003513038A (ja) 2003-04-08
DZ3249A1 (fr) 2001-05-10
SK7292002A3 (en) 2002-12-03
EP1225884A4 (en) 2005-06-15
AP2002002446A0 (en) 2002-03-31
WO2001032165A1 (en) 2001-05-10
CN1387433A (zh) 2002-12-25
HUP0203682A3 (en) 2003-10-28
CO5271676A1 (es) 2003-04-30
MA25562A1 (fr) 2002-10-01
PL355262A1 (en) 2004-04-05
NZ518002A (en) 2004-01-30
MXPA02004220A (es) 2002-10-17
AR026254A1 (es) 2003-02-05
US20030212112A1 (en) 2003-11-13

Similar Documents

Publication Publication Date Title
IL141445A0 (en) Benzazine derivatives as phosphodiesterase 4 inhibitors
EG23979A (en) Renin inhibitors
GB9900416D0 (en) Inhibitors
GB2321641B (en) Sulfamide-metalloprotease inhibitors
PL362903A1 (en) Renin inhibitors
IL148813A0 (en) Method for administering a phosphodiesterase 4 inhibitor
AU2274299A (en) Benzazine derivatives phosphodiesterase 4 inhibitors
HK1039124B (zh) 二氮雜萘衍生物磷酸二酯酶4抑制劑
HUP0000536A2 (en) Method for levelling a track
IL141446A0 (en) Benzazine derivatives as phosphodiesterase 4 inhibitors
EP1237112A4 (en) METHOD OF MAKING SECURE TRANSACTIONS ON ELECTRONIC BANKING BOOK (TIRELIRE)
MY133515A (en) Shim removing tool
EP1153022A4 (en) PROTEASE INHIBITORS
GB9925659D0 (en) A method of verification
HUP0200455A3 (en) Method for producing 4-amino-5-chloro-1-phenyl pyridazinone-(6)
GB9823341D0 (en) Process for phosphodiesterase iv inhibitors
GB9906058D0 (en) A method for the quantitative detrmination of D N A
GB9914436D0 (en) A method
GB9901166D0 (en) A set of parts
GB9922470D0 (en) A set of parts
HU9902898D0 (en) Method for influancing thermosensibility
HU9901405D0 (en) Method for economical gold-washing
GB9929341D0 (en) Inhibitors
GB9929340D0 (en) Inhibitors
GB9917294D0 (en) Inhibitors